AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC, HCC, immunologically cold tumors, and CCA. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; and AstraZeneca PLC. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
– Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief Medical Officer –...
– Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief Medical Officer –...
BOSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology , an LG Chem company (“AVEO”), today announced The Oncologist has published a post-hoc analysis of long-term progression free survival, over...
BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”), an LG Chem company, today announced enrollment of the first patient in the FIERCE-HN trial, a global, multicenter, randomized, dou...
We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022....
Here is how AVEO Pharmaceuticals (AVEO) and Merit Medical (MMSI) have performed compared to their sector so far this year....
AVEO Oncology (AVEO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well....
Does AVEO Pharmaceuticals (AVEO) have what it takes to be a top stock pick for momentum investors? Let's find out....
AVEO (AVEO) delivered earnings and revenue surprises of 43.75% and 1.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...